Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Single-arm, Open Label Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

NCT02124668 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.

NCT NCT02124668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02124668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Single-arm, Open Label Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Lead sponsor
Astellas Pharma Europe B.V.
Phase
Phase 2
Overall status
Completed
Start date
September 23, 2014
Completion date
May 25, 2017
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, prostate cancer